DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and West Pharmaceutical Services (NYSE:WST – Get Free Report) are both medical companies, but which is the superior business? We will compare the two ...

Swansea University has helped secure £22.4 million in funding from the Biotechnology and Biological Sciences Research Council ...

Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

Continuing our series speaking to senior executives who are transforming the pharma business model, pharmaphorum catches up with Dr Roch Doliveux, CEO of UCB, to find out what is the key to ...